Precision antimicrobial therapeutics: the path of least resistance?
暂无分享,去创建一个
Scott J. Hultgren | S. Hultgren | J. Janetka | R. Klein | James W. Janetka | Caitlin N. Spaulding | Roger D. Klein | Henry L. Schreiber | Caitlin N Spaulding | H. L. Schreiber
[1] R. Grüneberg. Relationship of infecting urinary organism to the faecal flora in patients with symptomatic urinary infection. , 1969, Lancet.
[2] R. Hartmann,et al. Glycomimetic, Orally Bioavailable LecB Inhibitors Block Biofilm Formation of Pseudomonas aeruginosa. , 2017, Journal of the American Chemical Society.
[3] Megan C. Garland,et al. A small-molecule antivirulence agent for treating Clostridium difficile infection , 2015, Science Translational Medicine.
[4] L. Bakaletz,et al. Microbial Interactions in the Respiratory Tract , 2009, The Pediatric infectious disease journal.
[5] D. Missiakas,et al. Small molecule inhibitor of lipoteichoic acid synthesis is an antibiotic for Gram-positive bacteria , 2013, Proceedings of the National Academy of Sciences.
[6] B. Nowicki,et al. Immunofluorescence study of fimbrial phase variation in Escherichia coli KS71 , 1984, Journal of bacteriology.
[7] M. Willmann,et al. Human commensals producing a novel antibiotic impair pathogen colonization , 2016, Nature.
[8] O. Coskun,et al. Recurrent Urinary Tract Infections. , 2008, American family physician.
[9] H. Goossens,et al. Antibiotic resistance—the need for global solutions , 2013, BDJ.
[10] R. Hartmann,et al. Novel Strategies for the Treatment of Pseudomonas aeruginosa Infections. , 2016, Journal of medicinal chemistry.
[11] S. Winter,et al. The dynamics of gut‐associated microbial communities during inflammation , 2013, EMBO reports.
[12] T. Rogers,et al. Staphylococcus aureus Colonization: Modulation of Host Immune Response and Impact on Human Vaccine Design , 2014, Front. Immunol..
[13] Alan P. Johnson,et al. Transferable resistance to colistin: a new but old threat. , 2016, The Journal of antimicrobial chemotherapy.
[14] N. Barnich,et al. Abnormal CEACAM6 expression in Crohn disease patients favors gut colonization and inflammation by Adherent-Invasive E. coli , 2010, Virulence.
[15] A. Macpherson,et al. Interactions Between the Microbiota and the Immune System , 2012, Science.
[16] Robert A. Weinstein,et al. The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace , 2017, The Journal of infectious diseases.
[17] E. Pamer,et al. Role of the commensal microbiota in normal and pathogenic host immune responses. , 2011, Cell host & microbe.
[18] Nicola K. Petty,et al. Chaperone-Usher Fimbriae of Escherichia coli , 2013, PloS one.
[19] S. Winter,et al. Streptomycin-Induced Inflammation Enhances Escherichia coli Gut Colonization Through Nitrate Respiration , 2013, mBio.
[20] D. Behar,et al. Diagnosis and treatment of urinary tract complications in Crohn's disease: an experience over 15 years. , 2002, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[21] Kelly J. Wright,et al. Development of intracellular bacterial communities of uropathogenic Escherichia coli depends on type 1 pili , 2007, Cellular microbiology.
[22] A. Schaeffer,et al. Role of type 1 pili and effects of phase variation on lower urinary tract infections produced by Escherichia coli , 1985, Infection and immunity.
[23] A. Feig,et al. Peptide inhibitors targeting Clostridium difficile toxins A and B. , 2010, ACS chemical biology.
[24] S. Hultgren,et al. Combinatorial Small-Molecule Therapy Prevents Uropathogenic Escherichia coli Catheter-Associated Urinary Tract Infections in Mice , 2012, Antimicrobial Agents and Chemotherapy.
[25] M. Blaser,et al. Risks of Antibiotic Exposures Early in Life on the Developing Microbiome , 2015, PLoS pathogens.
[26] Shadi Sepehri,et al. High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease , 2006, Gut.
[27] F. Bäckhed,et al. The gut microbiota — masters of host development and physiology , 2013, Nature Reviews Microbiology.
[28] James Kyle D.Sc.. Urinary complications of Crohn's disease , 2006, World Journal of Surgery.
[29] Roberta B Carey,et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. , 2007, JAMA.
[30] A. Sivignon,et al. Crohn's disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM , 2009, The Journal of experimental medicine.
[31] Wen-Chi Chou,et al. Bacterial virulence phenotypes of Escherichia coli and host susceptibility determine risk for urinary tract infections , 2017, Science Translational Medicine.
[32] D. Fremont,et al. Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist , 2017, Nature.
[33] T. Hooton. Clinical practice. Uncomplicated urinary tract infection. , 2012, The New England journal of medicine.
[34] S. Ladhani,et al. Non-typeable Haemophilus influenzae, an under-recognised pathogen. , 2014, The Lancet. Infectious diseases.
[35] M. Hogardt,et al. Pretreatment of Mice with Streptomycin Provides a Salmonella enterica Serovar Typhimurium Colitis Model That Allows Analysis of Both Pathogen and Host , 2003, Infection and Immunity.
[36] Eric P. Skaar,et al. Small Molecule Inhibitors of Staphylococcus aureus RnpA Alter Cellular mRNA Turnover, Exhibit Antimicrobial Activity, and Attenuate Pathogenesis , 2011, PLoS pathogens.
[37] James J Collins,et al. Antibiotics and the gut microbiota. , 2014, The Journal of clinical investigation.
[38] S. Péchiné,et al. Emerging monoclonal antibodies against Clostridium difficile infection , 2017, Expert opinion on biological therapy.
[39] D. Paterson,et al. The emerging threat of multidrug-resistant Gram-negative bacteria in urology , 2015, Nature Reviews Urology.
[40] Gopi Patel,et al. Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies , 2008, Infection Control & Hospital Epidemiology.
[41] M. Kawashima,et al. Propionibacterium acnes is developing gradual increase in resistance to oral tetracyclines , 2017, Journal of medical microbiology.
[42] H. Mobley,et al. In Vivo Dynamics of Type 1 Fimbria Regulation in UropathogenicEscherichia coli during Experimental Urinary Tract Infection , 2001, Infection and Immunity.
[43] Richard Bonnet,et al. Point Mutations in FimH Adhesin of Crohn's Disease-Associated Adherent-Invasive Escherichia coli Enhance Intestinal Inflammatory Response , 2013, PLoS pathogens.
[44] B. Finlay,et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. , 2007, Cell host & microbe.
[45] Cheng Luo,et al. Antiinfective therapy with a small molecule inhibitor of Staphylococcus aureus sortase , 2014, Proceedings of the National Academy of Sciences.
[46] Eric P. Skaar,et al. A Small-Molecule Inhibitor of Iron-Sulfur Cluster Assembly Uncovers a Link between Virulence Regulation and Metabolism in Staphylococcus aureus. , 2016, Cell chemical biology.
[47] A. Therien,et al. Small molecule inhibitors of Clostridium difficile toxin B-induced cellular damage. , 2015, Chemistry & biology.
[48] S. Beatson,et al. A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131. , 2013, The Journal of infectious diseases.
[49] Hui Wang,et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. , 2013, The Lancet. Infectious diseases.
[50] S. Hultgren,et al. Adhesive Pili in UTI Pathogenesis and Drug Development , 2016, Pathogens.
[51] M. Lensink,et al. The Antiadhesive Strategy in Crohn′s Disease: Orally Active Mannosides to Decolonize Pathogenic Escherichia coli from the Gut , 2016, Chembiochem : a European journal of chemical biology.
[52] P. Albertsen. Risk factors for recurrent urinary tract infection in young women. , 2003, The Journal of urology.
[53] Y. Takeda,et al. Genetic evidence supporting the fecal-perineal-urethral hypothesis in cystitis caused by Escherichia coli. , 1997, The Journal of urology.
[54] J. Crowley,et al. Treatment and Prevention of Urinary Tract Infection with Orally Active FimH Inhibitors , 2011, Science Translational Medicine.
[55] R. Knight,et al. The Human Microbiome Project , 2007, Nature.
[56] Sanjai J. Parikh,et al. Host-Derived Nitrate Boosts Growth of E. coli in the Inflamed Gut , 2013, Science.
[57] Howard Ochman,et al. Cospeciation of gut microbiota with hominids , 2016, Science.
[58] Liang Chen,et al. Colistin- and Carbapenem-Resistant Escherichia coli Harboring mcr-1 and blaNDM-5, Causing a Complicated Urinary Tract Infection in a Patient from the United States , 2016, mBio.
[59] N. Barnich,et al. CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. , 2007, The Journal of clinical investigation.
[60] H. Harrabi. Uncomplicated urinary tract infection. , 2012, The New England journal of medicine.
[61] J. Pinkner,et al. Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI , 2016, ChemMedChem.
[62] K. Kazmierczak,et al. Correlation of β-Lactamase Production and Colistin Resistance among Enterobacteriaceae Isolates from a Global Surveillance Program , 2015, Antimicrobial Agents and Chemotherapy.